1-6 of 6
Stephen Noga
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Free
Ajay Nooka, Nisha Joseph, Madhav Dhodapkar, Vikas Gupta, Craig Hofmeister, Manali Rupji, Bryan Burton, Hafsa Ahmed, Darrian Linton, Stephen Noga, Thomas Lin, Lawrence Boise, Jonathan Kaufman, Sagar Lonial
Journal: Blood
Blood (2025) 146 (Supplement 1): 5843.
https://doi.org/10.1182/blood-2025-5843
Published: 2025
Journal Articles

Patient-reported outcomes and actigraphy following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Subgroup analysis of US MM-6 by race/ethnicity, renal function, and area income

Free
Leon Bernal-Mizrachi, Ruemu Birhiray, Murtaza Bhuriwala, Robert Rifkin, Roger Lyons, Christopher Yasenchak, Stephen Noga, Isabel Ferreira, Dasha Cherepanov, Alexandra Savell, Yunlong Xie, Saulius Girnius
Journal: Blood
Blood (2025) 146 (Supplement 1): 4004.
https://doi.org/10.1182/blood-2025-4004
Published: 2025
Journal Articles

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy

Free
David Merola, Candice Yong, Stephen Noga, MD, Kenneth M Shermock, PhD PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3423.
https://doi.org/10.1182/blood.V130.Suppl_1.3423.3423
Published: 2017
Journal Articles

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

Free
Evangelos Terpos, MD PhD, Ajai Chari, MD, Robert M Rifkin, MD, Rafat Abonour, MD, Jesus G. Berdeja, MD, Mario Boccadoro, Gordon Cook, MD PhD, Caitlin Costello, MD, Saulius Girnius, MD, Hartmut Goldschmidt, MD, Roman Hájek, MD, Vania T M Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Jim Omel, MD, Andrew Spencer, MD, Michael A Thompson, MD, Saad Z Usmani, MD, Jorge Vela-Ojeda, MD PhD, Jeffrey A Zonder, MD, Liviu Niculescu, MD, Stephen Noga, MD, Tomas Skacel, MD, Roxanne Cacioppo, Brittany Sickler, BA, BS, Shawn Yu, Kaili Ren, PhD, Katarina Luptakova, MD, Dawn Marie Stull, Faith E. Davies, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5419.
https://doi.org/10.1182/blood.V130.Suppl_1.5419.5419
Published: 2017
Journal Articles

Determination of the Maximum Tolerated Dose of Cyclophosphamide in Conjunction with High-Dose Etoposide and Carboplatin Followed by Autologous CD34+ Hematopoietic Rescue in Pediatric Patients with Recurrent/Refractory Solid Tumors.

Free
Michelle P. Hudspeth, MD, Barbara Duffy, M.D., M.P.H., Stephen Noga, M.D., Ph.D., Steven Goodman, M.D., Ph.D, Curt I. Civin, M.D., Ph.D., Allen R. Chen, M.D., Ph.D., M.H.S.
Journal: Blood
Blood (2006) 108 (11): 5462.
https://doi.org/10.1182/blood.V108.11.5462.5462
Published: 2006
Journal Articles

Multicenter Phase III Trial to Evaluate CD34 + Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma

Free
Robert Vescio, Gary Schiller, A. Keith Stewart, Oscar Ballester, Stephen Noga, Hope Rugo, Cesar Freytes, Edward Stadtmauer, Stefano Tarantolo, Firoozeh Sahebi, Pat Stiff, Jacinta Meharchard, Robert Schlossman, Randy Brown, Heather Tully, Mark Benyunes, Cindy Jacobs, Ronald Berenson, John DiPersio, Ken Anderson, James Berenson
Journal: Blood
Blood (1999) 93 (6): 1858–1868.
https://doi.org/10.1182/blood.V93.6.1858.406k06_1858_1868
Published: 1999